Abstract | BACKGROUND: Two COX isoenzymes are known, COX-1 and COX-2, for which the main inhibitors are the NSAIDs. The common anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes. The COX-2 inhibitors represent a new class of drugs that do not affect COX-1 but selectively block COX-2. This selective action provides the benefits of reducing inflammation without irritating the stomach and cardiovascular effects. OBJECTIVE: This review focuses on patents published in the field during 2002 - 2008, paying particular attention to promising COX-2 inhibitors. CONCLUSION:
|
Authors | Teodorico C Ramalho, Marcus V J Rocha, Elaine F F da Cunha, Matheus P Freitas |
Journal | Expert opinion on therapeutic patents
(Expert Opin Ther Pat)
Vol. 19
Issue 9
Pg. 1193-228
(Sep 2009)
ISSN: 1744-7674 [Electronic] England |
PMID | 19563267
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Analgesics
- Cyclooxygenase 2 Inhibitors
- Cyclooxygenase 2
|
Topics |
- Analgesics
(adverse effects, pharmacology)
- Animals
- Cyclooxygenase 2
(drug effects, metabolism)
- Cyclooxygenase 2 Inhibitors
(adverse effects, pharmacology)
- Drug Delivery Systems
- Humans
- Inflammation
(drug therapy, physiopathology)
- Pain
(drug therapy, physiopathology)
- Patents as Topic
|